encycle_therapeutics_logorev

Our site is currently being worked on. Please try again at a later date.

JEFFREY COULL, PhD

President and CEO

Dr. Jeffrey Coull has served as Encycle’s President and CEO since 2013. He is also an Adjunct Professor at the University of Toronto. Prior to joining Encycle, Jeff co-founded Chlorion Pharma, a venture-backed drug discovery company focused on neuropathic pain and epilepsy, and KineRx Neurosciences, a specialty pharmaceutical company that acquired the rights to a marketed movement disorder therapeutic. He holds a PhD in pharmacology from McGill University, and, upon convocation, received a Doctoral Prize from the Natural Sciences and Engineering Research Council of Canada, the countries highest distinction for doctoral research.

Andrei Yudin, PhD

President and CEO

Dr. Andrei Yudin founded Encycle in 2012 to apply and commercialize the proprietary synthetic methods he and his colleagues invented. He is a Professor in the Department of Chemistry at the University of Toronto, a Fellow of the Royal Society of Canada, and currently serves as Chair of the Board for Organic and Biomolecular Chemistry. Andrei has also received several major awards, including the 2010 Rutherford Medal and the 2015 Bernard Belleau Award in Medicinal Chemistry. He holds a PhD in chemistry from the University of Southern California, where he worked under the direction of Nobel Laureate Professor George A. Olah, and served as a postdoctoral fellow in the laboratory of Nobel Laureate Professor K. Barry Sharpless at the Scripps Research Institute.

Raphael Hofstein, PhD

President and CEO

Dr. Raphael Hofstein is Chairman of the Board at Encycle and serves as President and CEO at MaRS Innovation, which, along with Professor Yudin, was instrumental in the formation and seeding of Encycle Therapeutics in 2012. Rafi also serves on several other boards, including TriPhase Accelerator Corporation, Life Sciences Ontario and Quebec Consortium for Drug Discovery. Prior to taking the helm at MaRS Innovation, he held various senior roles at Ecogen in Langhorne, PA and in Israel, and was President and CEO of Hadasit, the commercialization company of Hadassah, the largest teaching hospital in Israel, among other positions in the life sciences. Rafi received his PhD in Life Sciences and Chemistry from the Weizmann Institute of Science.

Andrew Roughton, PhD

Vice President, Discovery and Operations, Encycle Therapeutics
Observer

Dr. Andrew Roughton is Encycle’s Vice President of Discovery and Operations and was the company’s first full-time employee. Before joining Encycle, he was a Senior Medicinal Chemist at Dalton Medicinal Chemistry, and previously, spent nearly 15 years as a Senior Principal Scientist at Pharmacopeia in Princeton, NJ. During this time Andrew was also a founding member and secretary of the NJ Biotechnology Chemistry Consortium. He completed his PhD in organic chemistry at the Max-Planck-Institut (Mūlheim a.d. Ruhr / Universität Essen) under Professors Martin Demuth and Kurt Schaffner, and a post-doctoral fellowship at Eidgenössische Technische Hochschule Zurich (ETH), where he focused on bioorganic chemistry under the guidance of Professor Steven Benner.